Abstract
A series of mono and bis-2-(2-(dimethylamino)-ethyl)-5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-diones with different amino side chains, a novel family of antitumor agents, has been designed and synthesized. Their antitumor activity was evaluated against HeLa, A549, P388, HL-60, MCF-7, HCT-8, and A375 cancer cell lines in vitro. Preliminary results showed that most of the derivatives had antitumor activity comparable with that of mitonafide, with IC 50 values of 10−6–10−5 M. More importantly, the derivatives had distinct antitumor selectivity against different cancer cell lines. This work provided a novel class of mitonafide-based lead compounds with improved antitumor selectivity against cancer cell lines for further optimization.
Graphical Abstract
Similar content being viewed by others
References
Hurley LH (2002) Nat Rev Cancer 2:188
Tao ZF, Lin NH (2006) Anticancer Agents Med Chem 6:377
Wu AB, Xu YF, Qian XH (2009) Bioorg Med Chem 17:592
Braña MF, Ramos A (2001) Curr Med Chem Anticancer Agents 1:237
Braña MF, Cacho M, Gradillas A, de Pascual-Teresa B, Ramos A (2001) Curr Pharm Des 7:1745
Quaquebeke EV, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, Yazidi ME, Vynckt FV, Mijatovic T, Lefranc F, Darro F, Kiss R (2007) J Med Chem 50:4122
Hsiang YH, Jiang JB, Liu LF (1989) Mol Pharmacol 36:371
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J (1991) Clin Pharmacol Ther 50:573
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB (1993) Cancer Res 53:2304
Bolognesi ML, Calonghi N, Mangano C, Masotti L, Melchiorre C (2008) J Med Chem 51:5463
Paul A, Vicent MJ, Duncan R (2007) Biomacromolecules 8:1573
Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, Ding J (2007) Mol Cancer Ther 6:484
Yin H, Xu YF, Qian XH (2007) Bioorg Med Chem 15:1356
Song L, Bevins R, Anderson BD (2006) J Med Chem 49:4344
Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, Emerson A, Fanelli F, Gohlke H, Kuhn LA, Morris GM, Orozco M, Pertinhez TA, Rizzi M, Sotriffer CA (2008) J Med Chem 51:6237
Bollini M, Casal JJ, Bruno AM (2008) Bioorg Med Chem 16:8003
Antonini I, Volpini R, Ben DD, Lambertucci C, Cristalli G (2008) Bioorg Med Chem 16:8440
Wilhelmsson LM, Kingi N, Bergman J (2008) J Med Chem 51:7744
Norton JT, Witschi MA, Luong L, Kawamura A, Ghosh S, Stack MS, Sim E, Avram MJ, Appella DH, Huang S (2008) Anticancer Drug 19:23
Noël G, Godon C, Fernet M, Giocanti N, Mégnin-Chanet F, Favaudon V (2006) Mol Cancer Ther 5:564
Yang P, Yang Q, Qian XH (2005) Tetrahedron 61:11895
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) J Natl Cancer Inst 82:1107
Kuroda M, Mimaki Y, Sashida Y, Hirano T, Oka K, Dobashi A (1997) Tetrahedron 53:11549
Acknowledgments
This work was supported by the National Natural Science Foundation of China (90713026) and by Yangtze University.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wu, A., Liu, J., Qin, S. et al. Derivatives of 5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione: design, synthesis, and biological activity. Monatsh Chem 141, 95–99 (2010). https://doi.org/10.1007/s00706-009-0220-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00706-009-0220-9